How would you consider use of high dose IL-2 for metastatic renal cell carcinoma, in light of novel checkpoint therapy combinations now available?

In the context of significant favorable impacts of PD-1 combinations for RCC treatment, including [in alphabetical order] axitinib/avelumab, axitinib/pembrolizumab, cabozantinib/nivolumab, and ipilumimab/nivolumab and [to this point non-randomized data for lenvatinib/pembrolizumab], there remains the known strikingly durable complete response history for high dose IL-2 treatment. The treatment populations in those newer combinations have been selected in a way that is strikingly different than most IL-2 series; this is particularly more favorable with the PD-1 combinations for intermediate and high-risk clear cell RCC, also including some durable complete responses. On the other hand, for good-risk patients, there may be little advantage (q...